Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 144

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 144
---
 and changes in our operating assets and liabilities of $2.7 million, partially offset by $1.4 million of non-cash charges related to stock-based compensation, depreciation and
amortization of discounts on marketable securities.

Investing Activities

Net cash used in investing activities was $142.1 million during the nine months ended September 30, 2024, which was primarily driven by
purchases of marketable securities of $175.6 million, partially offset by maturities of marketable securities of $33.5 million.

Net cash
provided by investing activities was $20.2 million during the nine months ended September 30, 2023, which was primarily driven by maturities of marketable securities of $44.8 million, partially offset by purchases of marketable
securities for $23.5 million and purchases of property and equipment of $1.0 million.

Net cash provided by investing activities was
$27.4 million during the year ended December 31, 2023, which was primarily driven by maturities of marketable securities of $52.0 million, partially offset by purchases of marketable securities for $23.5 million and purchases of
property and equipment of $1.1 million.

Net cash used in investing activities was $29.3 million during the year ended December 31,
2022, which was primarily driven by purchases of marketable securities for $40.4 million and property and equipment of $1.9 million, partially offset by cash provided from maturities of marketable securities of $13.0 million.

Financing Activities

Net cash provided by financing
activities was $180.4 million during the nine months ended September 30, 2024, as compared to $31,000 during the nine months ended September 30, 2023. The increase in net cash provided by financing activities was primarily due to the
Series C Financing which occurred in March 2024, compared to no financings completed during 2023, partially offset by $1.1 million of payments of offering costs.

Net cash provided by financing activities was $31,000 during the year ended December 31, 2023, as compared to $110.9 million during the year
ended December 31, 2022. The decrease in net cash provided by financing activities was primarily due to the fact that the Series B financing occurred in 2022 and no financings occurred in 2023.

Future Funding Requirements